Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Murata Masayuki Last modified date:2021.10.29

Lecturer / Environmental Medicine and Infectious Diseases, Internal Medicine
General Internal Medicine
Kyushu University Hospital

 Reseacher Profiling Tool Kyushu University Pure
Academic Degree
doctor of philosophy
Country of degree conferring institution (Overseas)
Field of Specialization
General internal medicine, Infectious disease, Infection control, HIV/AIDS, Viral hepatitis, clinical immunology, Lifestyle diseases
Total Priod of education and research career in the foreign country
Outline Activities
I examine new patients in the department of general internal medicine.

I analyse for the pathogenesis of HIV infection and chronic hepatitis B or C by immunobiological and epidemiological methods. I belong to the Center for the study of global infection, Kyushu university hospital, and support appropriate use of antimicrobials in patients with bacteremia or sepsis and am involved in the antimicrobial resistance (AMR) surveillance.

I educate general internal medicine, primary care, infectious diseases and nosocomial infection control as a physician.

I make a social contributionI through the mass examination in which I perform esophagogastroduodenoendoscopy, abdominal or carotid artery ultrasonography.
Research Interests
  • Analysis for HIV infection and non-communicable diseases
    keyword : HIV, ageing, non-communicable diseases
  • Molecular epidemiological analysis for SCCmec type IV MRSA in Japan
    keyword : MRSA、community-acquired MRSA、SCCmec IV
  • Analysis for the efficacy and safety of peginterferon-alpha-2a monotherapy on chronic active hepatitis B patients
    keyword : HBV, peginterferon-alpha
  • HCV/HIV coinfection
    keyword : Chronic hepatitis C, HIV infection
  • HBV/HIV coinfection
    keyword : HBV, HIV
  • Healthcare-associated infections
    keyword : nosocomical infections, MRSA
  • pathogenesis of HIV infection
    keyword : HIV, AIDS
Academic Activities
1. Fujiko Mitsumoto-Kaseida, Masayuki Murata, Koji Takayama, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients, Journal of Infection and Chemotherapy, 10.1016/j.jiac.2019.06.003, 26, 1, 28-32, 2020.01, Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients..
2. Fujiko Mitsumoto, Masayuki Murata, kazuya Ura, Koji Takayama, Satoshi Hiramine, Motohiro Shimizu, Toyoda K, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 10.1016/j.jiac.2014.12.003, 21, 3-4, 264-271, 2015.04.
3. 村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of
telaprevir-based triple therapy for a hemophilia patient with hepatitis C
virus/human immunodeficiency virus co-infection who previously failed pegylated
interferon-α and ribavirin therapy, 10.1016/j.jiac.2013.11.006., 20, 5, 320-324, 2014.05.
4. 村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy., doi: 10.1016/j.jiac.2013.11.006., 2013.11, In Japan, the human immunodeficiency virus (HIV) and hepatitis C virus (HCV)
coinfection of some patients with hemophilia was caused by the transfusion of
imported blood products, such as unheated coagulation factor. With the
development of antiretroviral therapy (ART) for HIV, chronic HCV infection has
become a major cause of liver disease and mortality for hemophiliac patients
coinfected with HCV/HIV. Data is limited regarding the efficacy and safety of
antiviral therapy with the HCV protease inhibitor telaprevir (TVR) in combination
with pegylated interferon-α (PegIFN-α) and ribavirin (RBV) for hemophilia
patients coinfected with HCV/HIV. We report a case of a Japanese patient with
hemophilia and HCV/HIV coinfection who had partial response to prior to PegIFN-α
and RBV therapy. This is the first published report of 24-week TVR-based triple
therapy for a hemophilia patient coinfected with HCV/HIV. The patient had HCV
genotype 1a infection with a high viral load. His single-nucleotide polymorphism
of the interleukin 28B (rs8099917) gene was the TT major allele. He presented
with undetectable HIV RNA and a high CD4(+) T cell counts by taking ART including
tenofovir, emtricitabine and raltegravir. He was again treated for HCV with TVR
plus PegIFN-α2b and RBV for the first 12 weeks, followed by the continuation of
PegIFN-α2b and RBV for 12 additional weeks while continuing ART. He had rapid
virological response and achieved sustained virological response with the 24-week
treatment. No serious adverse events such as skin rash, severe anemia or
exacerbated bleeding tendency were observed, only a mild headache. No dose
adjustment was necessary when tenofovir and raltegravir were used in combined
with TVR, and no HIV breakthrough was observed. TVR-based triple therapy with ART
could can an effective treatment for hemophilia patients coinfected with HCV
(genotype 1)/HIV regardless of prior response. TVR can be used in combination
with tenofovir, emtricitabine and raltegravir for patients with hemophilia.
Furthermore, patients with undetectable HCV RNA at week 4 could be successfully
treated with a 24-week regimen..
5. Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J., Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients., World J Gastroenterol. 2011 Jun 28;17(24):2945-52., 17, 24, 2945-52, 2011.06, AIM:
To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate (YMDD) mutants (reverse transcription; rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus (HBV) infection.
The data of 61 consecutive Japanese patients with chronic hepatitis B who underwent continuous lamivudine treatment for more than 24 mo and had a virological response were analyzed. Analysis of YMDD mutants was done by real-time polymerase chain reaction with LightCycler probe hybridization assay for up to 90 mo (mean, 50.8 mo; range, 24-90 mo).
A mixed mutant-type (YMDD + tyrosine-isoleucine-asparatate-asparatate: YIDD or tyrosine-valine-asparatate-asparatate: YVDD) or a mutant-type (YIDD or YVDD) were found in 57.4% of 61 patients at 1 year, 78.7% of 61 patients at 2 years, 79.6% of 49 patients at 3 years, 70.5% of 34 patients at 4 years, 68.4% of 19 patients at 5 years, 57.1% of 14 patients at 6 years, and 33.3% of 6 patients at 7 years. Of the 61 patients, 56 (92%) had mixed mutant- or a mutant-type. Only 5 (8%) had no mutants at each observation point. Virological breakthrough was found in 26 (46.4%) of 56 patients with YMDD mutants, 20 of whom had a hepatitis flare-up: the remaining 30 (53.6%) had neither a virological breakthrough nor a flare-up. All 20 patients who developed a hepatitis flare-up had a biochemical and virological response after adefovir was added to the lamivudine treatment.
Our results suggest that it is possible to continue lamivudine treatment, even after the emergence of YMDD mutants, up to the time that the patients develop a hepatitis flare-up..
1. Murata Masayuki, Recent trends in Influenza, 14th East Asian Conference on Infection Control and Prevention (EACIC) 2015, 2015.11.
2. The aim of this study was to determine the efficacy of PegIFN-alpha plus RBV treatment for Japanese patients infected with HCV. In total, 201 patients with genotype 1 and HCV RNA level 100 kIU/mL or over received PegIFN-alpha subcutaneously once a weekly and daily RBV for 48 weeks. The overall sustained virological response (SVR) (undetectable serum HCV RNA) 24 weeks after end of treatment was 41.8% by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without discontinuation of the 48-week treatment (48.4% vs. 20.8%), but no difference was found between those with and without a dose reduction of these drugs. Multiple regression analysis showed younger age, lower gamma-glutamyltransferase, higher platelet count at baseline to be significantly independent parameters associated with SVR. The low gamma-glutamyltransferase is an independent predictive SVR factor newly added to the usual ones in PegIFN-alpha plus RBV treatment for Japanese chronically HCV-infected patients..
Membership in Academic Society
  • Japanese society of General Hospital Medicine
  • Japanese society of Travel and Health
Educational Activities
General medicine
Primary care
Infectious diseases and infection control
Viral hepatitis
Professional and Outreach Activities
The cooperation to the community health business.